Market Price

168.57 

-1.59 -0.9%

as of May 26 '20

52 Week Range:

98.02 196.36


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, and medical drug monitoring; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides technology-enabled solutions, including a suite of applications to enable patients, healthcare providers, health systems, accountable care organizations, and insurers with convenient and secure access to LCD's data and services, as well as billing for laboratory services. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, academic institutions, and independent clinical laboratories. Laboratory Corporation of America Holdings has collaborations with the Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, Yale University, and QIAGEN N.V. The company was founded in 1971 and is headquartered in Burlington, North Carolina.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Equity (BVPS) 20.00
24.09
26.01
29.06
29.94
32.75
48.50
53.78
60.12
73.29
74.39
growth rate 20.5% 8.0% 11.7% 3.0% 9.4% 48.1% 10.9% 11.8% 21.9% 1.5%
Earnings BIT 884.60
915.60
866.10
944.20
915.60
945.50
1,264.10
1,368.90
1,376.10
1,461.60
1,465.20
growth rate 3.5% -5.4% 9.0% -3.0% 3.3% 33.7% 8.3% 0.5% 6.2% 0.3%
Avg.PE 15.04
16.61
16.84
14.47
14.62
20.82
25.85
20.27
13.99
17.44
21.88
growth rate 10.4% 1.4% -14.1% 1.0% 42.4% 24.2% -21.6% -31.0% 24.7% 25.5%
ROA 11.43
10.13
8.43
9.02
8.34
7.17
4.06
5.14
8.23
5.40
4.81
growth rate -11.4% -16.8% 7.0% -7.5% -14.0% -43.4% 26.6% 60.1% -34.4% -10.9%
ROE 28.64
24.42
20.91
22.34
22.03
19.25
11.25
14.01
20.56
12.81
11.33
growth rate -14.7% -14.4% 6.8% -1.4% -12.6% -41.6% 24.5% 46.8% -37.7% -11.6%
ROIC 16.84
14.74
12.23
12.71
11.68
10.21
6.99
7.72
11.30
7.92
7.24
growth rate -12.5% -17.0% 3.9% -8.1% -12.6% -31.5% 10.4% 46.4% -29.9% -8.6%
Cur. Ratio 0.92
1.02
1.36
1.35
1.95
1.73
1.57
1.36
1.31
1.51
1.12
growth rate 10.9% 33.3% -0.7% 44.4% -11.3% -9.3% -13.4% -3.7% 15.3% -25.8%
Quick Ratio 0.71
0.79
1.08
1.15
1.62
1.43
1.23
1.07
0.99
1.22
0.89
growth rate 11.3% 36.7% 6.5% 40.9% -11.7% -14.0% -13.0% -7.5% 23.2% -27.1%
Leverage 2.30
2.51
2.45
2.50
2.80
2.59
2.88
2.59
2.43
2.32
2.38
growth rate 9.1% -2.4% 2.0% 12.0% -7.5% 11.2% -10.1% -6.2% -4.5% 2.6%
Balance Sheet Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Acct.Receivable 574.20
655.60
710.30
729.40
784.70
815.70
1,374.50
1,518.70
1,847.50
1,862.30
2,025.30
growth rate 14.2% 8.3% 2.7% 7.6% 4.0% 68.5% 10.5% 21.7% 0.8% 8.8%
Acct.Payable 597.10
548.50
624.40
282.30
497.40
508.40
573.90
634.60
632.30
growth rate -8.1% 13.8% -54.8% 76.2% 2.2% 12.9% 10.6% -0.4%
Cur.Assets 935.60
1,143.80
1,060.00
1,391.80
1,432.10
1,692.70
2,621.20
2,478.70
2,733.80
2,835.40
2,981.20
growth rate 22.3% -7.3% 31.3% 2.9% 18.2% 54.9% -5.4% 10.3% 3.7% 5.1%
Total Assets 4,837.80
6,187.80
6,111.80
6,795.00
6,965.90
7,301.80
14,104.70
14,247.00
16,673.00
16,185.30
18,046.40
growth rate 27.9% -1.2% 11.2% 2.5% 4.8% 93.2% 1.0% 17.0% -2.9% 11.5%
Cash 148.50
230.70
159.30
466.80
404.00
580.00
716.40
433.60
316.60
426.80
337.50
growth rate 55.4% -31.0% 193.0% -13.5% 43.6% 23.5% -39.5% -27.0% 34.8% -20.9%
Inventory 90.00
103.40
110.80
121.00
136.50
139.50
191.00
205.20
227.20
237.30
244.70
growth rate 14.9% 7.2% 9.2% 12.8% 2.2% 36.9% 7.4% 10.7% 4.5% 3.1%
Cur.Liabilities 1,018.40
1,120.50
732.60
1,028.50
735.70
976.30
1,700.50
1,827.60
2,185.70
1,878.90
2,655.80
growth rate 10.0% -34.6% 40.4% -28.5% 32.7% 74.2% 7.5% 19.6% -14.0% 41.4%
Liabilities 2,731.70
3,721.50
3,608.30
4,077.60
4,474.60
4,463.60
9,144.70
8,726.00
9,848.10
9,194.80
10,459.30
growth rate 36.2% -3.0% 13.0% 9.7% -0.3% 104.9% -4.6% 12.9% -6.6% 13.8%
LT Debt 977.20
1,826.70
2,085.50
2,175.00
2,889.10
2,643.50
5,884.80
5,243.80
6,286.80
5,990.90
5,789.80
growth rate 86.9% 14.2% 4.3% 32.8% -8.5% 122.6% -10.9% 19.9% -4.7% -3.4%
Equity 2,106.10
2,466.30
2,503.50
2,717.40
2,491.30
2,820.50
4,945.10
5,505.80
6,804.10
6,971.40
7,567.00
growth rate 17.1% 1.5% 8.5% -8.3% 13.2% 75.3% 11.3% 23.6% 2.5% 8.5%
Common Shares 109.00
105.00
101.00
97.00
91.00
86.00
100.00
104.00
104.00
102.00
98.00
growth rate -3.7% -3.8% -4.0% -6.2% -5.5% 16.3% 4.0% 0.0% -1.9% -3.9%
Cash Flow Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Capital Expenditures 114.70
126.50
145.70
173.80
202.20
203.50
255.80
278.90
312.90
379.80
400.20
growth rate 10.3% 15.2% 19.3% 16.3% 0.6% 25.7% 9.0% 12.2% 21.4% 5.4%
Cash Dividends 0.00
12.60
7.40
1.20
0.90
1.20
2.10
2.10
1.00
growth rate -41.3% -83.8% -25.0% 33.3% 75.0% 0.0% -52.4%
Cash From OA 862.40
883.60
855.60
841.40
818.70
739.00
982.40
1,197.10
1,498.10
1,305.40
1,444.70
growth rate 2.5% -3.2% -1.7% -2.7% -9.7% 32.9% 21.9% 25.1% -12.9% 10.7%
FCF per Share 6.85
7.18
6.67
6.83
6.62
6.41
6.17
7.90
10.10
9.60
9.73
growth rate 4.8% -7.1% 2.4% -3.1% -3.2% -3.7% 28.0% 27.9% -5.0% 1.4%
Sale Purchase of Stock -525.50
-430.70
-841.60
114.80
98.90
70.60
73.60
growth rate 0.0% 0.0% 100.0% -13.9% -28.6% 4.3%
FCF 748.00
757.00
709.00
665.00
617.00
536.00
727.00
897.00
1,144.00
926.00
1,045.00
growth rate 1.2% -6.3% -6.2% -7.2% -13.1% 35.6% 23.4% 27.5% -19.1% 12.9%
Income Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Sales 4,694.70
5,003.90
5,542.30
5,671.40
5,808.30
6,011.60
8,505.70
9,552.90
10,308.00
11,333.40
11,554.80
growth rate 6.6% 10.8% 2.3% 2.4% 3.5% 41.5% 12.3% 7.9% 10.0% 2.0%
Op.Income 935.90
978.80
529.20
604.50
590.70
945.50
1,264.10
1,368.90
1,376.10
1,461.60
1,465.20
growth rate 4.6% -45.9% 14.2% -2.3% 60.1% 33.7% 8.3% 0.5% 6.2% 0.3%
IBT 884.60
915.60
866.10
944.20
915.60
820.60
726.00
1,073.60
1,077.50
1,268.30
1,104.90
growth rate 3.5% -5.4% 9.0% -3.0% -10.4% -11.5% 47.9% 0.4% 17.7% -12.9%
Net Income 543.30
558.20
529.20
604.50
590.70
511.20
437.60
711.80
1,227.10
883.70
823.80
growth rate 2.7% -5.2% 14.2% -2.3% -13.5% -14.4% 62.7% 72.4% -28.0% -6.8%
EPS 4.98
5.29
5.11
5.99
6.25
5.91
4.35
6.82
11.81
8.61
8.35
growth rate 6.2% -3.4% 17.2% 4.3% -5.4% -26.4% 56.8% 73.2% -27.1% -3.0%
Gross Profit 1,970.90
2,097.80
2,274.70
2,249.70
2,223.20
2,203.10
2,903.30
2,854.00
3,091.80
3,176.40
3,252.50
growth rate 6.4% 8.4% -1.1% -1.2% -0.9% 31.8% -1.7% 8.3% 2.7% 2.4%

Quarterly Statements

Item Name Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Earnings BIT 353.70
386.60
357.50
367.40
270.20
growth rate 9.3% -7.5% 2.8% -26.5%
Balance Sheet Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Acct.Receivable 1,985.70
2,064.90
2,094.10
2,025.30
1,960.30
growth rate 4.0% 1.4% -3.3% -3.2%
Acct.Payable 592.20
531.60
607.80
632.30
568.70
growth rate -10.2% 14.3% 4.0% -10.1%
Cur.Assets 2,885.30
2,848.60
2,987.80
2,981.20
2,891.10
growth rate -1.3% 4.9% -0.2% -3.0%
Total Assets 16,970.80
17,744.40
17,847.80
18,046.40
17,298.40
growth rate 4.6% 0.6% 1.1% -4.1%
Cash 348.80
265.40
361.10
337.50
323.60
growth rate -23.9% 36.1% -6.5% -4.1%
Inventory 233.70
219.70
234.90
244.70
254.00
growth rate -6.0% 6.9% 4.2% 3.8%
Cur.Liabilities 2,526.90
2,495.80
2,554.90
2,655.80
2,458.00
growth rate -1.2% 2.4% 4.0% -7.5%
Liabilities 9,840.00
10,580.00
10,597.00
10,459.30
10,259.80
growth rate 7.5% 0.2% -1.3% -1.9%
LT Debt 5,496.20
6,135.00
6,101.30
5,789.80
5,790.20
growth rate 11.6% -0.6% -5.1% 0.0%
Equity 7,111.30
7,144.40
7,231.10
7,567.00
7,020.10
growth rate 0.5% 1.2% 4.7% -7.2%
Common Shares 11.60
9.10
9.00
9.00
9.00
growth rate -21.6% -1.1% 0.0% 0.0%
Cash Flow Statement Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Capital Expenditures 94.20
85.20
92.60
128.20
106.60
growth rate -9.6% 8.7% 38.4% -16.9%
Cash Dividends
growth rate
Cash From OA 165.80
253.50
455.60
569.80
203.80
growth rate 52.9% 79.7% 25.1% -64.2%
Sale Purchase of Stock
growth rate
FCF 71.60
168.30
363.00
441.60
97.20
growth rate 135.1% 115.7% 21.7% -78.0%
Income Statement Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Sales 2,791.20
2,881.70
2,928.50
2,953.40
2,823.80
growth rate 3.2% 1.6% 0.9% -4.4%
Op.Income 353.70
386.60
357.50
367.40
270.20
growth rate 9.3% -7.5% 2.8% -26.5%
IBT 254.70
270.00
287.40
292.90
-267.70
growth rate 6.0% 6.4% 1.9% -100.0%
Net Income 185.60
190.40
220.70
227.10
-317.20
growth rate 2.6% 15.9% 2.9% -100.0%
EPS
growth rate
Gross Profit 789.70
824.80
817.30
820.70
728.00
growth rate 4.4% -0.9% 0.4% -11.3%
R&D
growth rate

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

C (62.06)

YOY Growth Grade:

D (40.69)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 21.88 22.21 13.82
EPS / Growth 9.2% 7.59 11.4%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 13.6%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 9.2% 11.4% 11.4%
Future PE 13.82 19.49 19.49
Future EPS 18.22 22.30 22.30
Value Price
MOS %
62.24
-63.1%
107.43
-36.3%
107.43
-36.3%
MOS Price 31.12 53.72 53.72
IRT 12.01 10.99 10.99

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.